Live
Tarsus Pharmaceuticals, Inc.
Healthcare · Biotechnology · NASDAQ
1260 candles · 5Y · retrieved
Estimated fair value
605.33
Range
256.88–1,320.45
Price vs value
631% below
Model support
Value
631% below fair value
confidence low
Estimate momentum
▲ improving
Next catalyst
none scheduled
Volatility
calm
regime
1M forecast
withheld
Value tells you the size of the gap; the other cells tell you what could close it — and when. A cheap stock without a catalyst can stay cheap.
Forecast withheld
stale data
No intelligence items published yet.
Price trades 631% below the fair-value estimate — TARS screens as materially undervalued. Only one valuation model is applicable here, so there is no independent cross-check. A valuation gap is not a timing signal and currently has zero ranking weight.
Forward earnings lens
56.5x FY2027 P/E
EPS 1.474 analysts
Shown as context, not blended into fair value, while genuine point-in-time forward-multiple history accumulates.
Where estimates sit vs price 82.76
Not meaningful for this company type: cash-flow model (dcf), trailing earnings x own 5y p/e, peer companies' ev/ebitda, excess returns model (financials), dividend discount model, total payout (dividends + net buybacks), p/ocf vs peer reits (ffo proxy).
Cheap or expensive — depending on the yardstick
Entry threshold
below 484.26(fair value 605.33 − 20%)
price is inside your band
A valuation threshold, not a timing signal — a cheap stock can keep falling. Alerts wire in when the notification substrate lands.
▲ Estimates improving (revenue +1.7% · EPS +55.3% · targets +2.3% this month)